Project description:Treatment of the acute T cell leukemia cell line Jurkat in vitro with the most potent histone deacetylase inhibitor, Trichostatin A induced apoptosis in a dose-dependent manner. Analysis of the drug-treated Jurkat cells using high throughput genome-wide gene expression profiling indicated the upregulation as well as downregulation of several genes crucial for cellular functions. Use of quantitative reverse transcriptase-mediated polymerase chain reaction validated the regulation of selected genes in drug-treated cells. Collectively, this study has unraveled the genes involved in epigenetic regulation of the T cell leukemia. Microarray analysis was performed to determine the changes in global gene expression profiles during apoptosis of a T cell leukemia induced by the histone deacetylase inhibitor, Trichostatin A. Drug treatment induced the upregulation and repression of a number of genes.
Project description:Large biological heterogeneity hallmarks acute myeloid leukemia (AML) and substantially hampers development of novel comprehensive therapies. While all-trans retinoic acid (ATRA) revolutionized therapy of acute promyelocytic leukemia, its impact on other AML subtypes remained largely disappointing. Here we show for the first time that ATRA mediated phosphorylation of the histone demethylase PHF8 induces apoptosis of AML cells of different subtypes via regulation of viral mimicry and subsequent initiation of interferon (IFN) type-I response. Phospho-PHF8 conferred H3K9me2 demethylation at promoter sites of key initiators of cell-intrinsic immune response. Multiomics based analyses revealed activation of cytosolic RNA sensors as key step towards NF-κB driven IFN type-I mediated apoptosis. Epigenetic changes directed by PHF8 also induced a specific proteosome pathway controlling NF-κB activity after its initial activation. Hence, PHF8 orchestrates viral mimicry, triggering IFN type-I response-differentiation-apoptotic network in a broad spectrum of AML when activated by ATRA. Forced phosphorylation of PHF8 via combination treatment with ATRA and simultaneous pharmacological inhibition of PHF8 dephosphorylation significantly impaired growth of human AML. Our findings finally open the gate for successful application of ATRA-based combination therapies in AML.